SEC Filing Summary
Issuer and period: The supplied filing is Spherix Incorporated and subsidiaries’ unaudited Form 10-Q for the quarter ended March 31, 2016—not a filing identified as Dominari Holdings Inc. The filing describes Spherix as an intellectual-property patent commercialization company.
Financial results and position
- Revenue: $72,000, compared with nominal revenue of $2,000 in Q1 2015. The 2016 revenue was recognized over time from the RPX patent license agreement.
- Operating results: Operating expenses were $1.633 million and operating loss was $1.561 million, versus expenses of $4.118 million and operating loss of $4.116 million in Q1 2015. Lower patent amortization, following a $38.9 million impairment recorded in 2015, was the main reason for the improvement.
- Net result: Net loss was $49,000, compared with $4.086 million. A $1.542 million noncash gain from the change in fair value of warrant liabilities substantially offset the operating loss. A $667,000 deemed dividend on Series K preferred conversion brought net loss attributable to common stockholders to $716,000, or $0.26 per share, versus $4.086 million, or $2.71 per share. The MD&A separately describes common-stockholder net loss as approximately $0.1 million; the financial statements provide the clearer figure of $716,000.
- Cash flow: Operating activities used $1.516 million, versus $1.337 million used in Q1 2015. Investing activities provided $1.868 million, mainly from net sales of marketable securities. There were no financing cash flows in either period. Cash increased by $352,000 to $494,000.
- Liquidity and assets: At quarter-end, cash was $494,000 and marketable securities were $1.468 million, down from $142,000 and $3.392 million, respectively, at year-end 2015. Working capital deficit was approximately $100,000, improved from $600,000. Total assets were $11.555 million, including $9.268 million of net patent assets.
- Liabilities and equity: Total liabilities were $2.723 million, including $1.417 million of warrant liabilities and $362,000 of current and long-term lease liabilities. The balance sheet reports no conventional borrowing. Accumulated deficit was $135.322 million. No meaningful gross margin is presented for this licensing business.
Material changes and notable items
- Warrant liabilities fell from $2.959 million to $1.417 million; the $1.542 million fair-value adjustment was recorded as other income and was not operating cash generation.
- During the quarter, 1,190 Series K preferred shares converted into 313,157 common shares, with a $667,000 deemed dividend recognized. The filing reports 2,962,768 common shares outstanding at March 31; 2,975,926 were outstanding as of May 13.
- A 1-for-19 reverse stock split took effect March 4, 2016, and Spherix regained Nasdaq’s minimum-bid-price compliance in March. The filing says the split-adjusted share and per-share data are reflected retrospectively.
- The 2015 RPX agreement canceled the remaining Series I preferred stock and its $5 million redemption obligation, canceled a security interest in 101 patents, and provided $300,000 cash. Spherix recognized $72,000 of license revenue in the quarter and expected to recognize the remaining deferred revenue over the relevant obligation period. A standstill restricting certain patent actions and transfers ran through May 23, 2016.
Outlook, risks, contingencies and controls
- Going concern: Management states that recurring losses and operating cash deficits raise substantial doubt about Spherix’s ability to continue as a going concern. Existing liquidity is not sufficient for foreseeable operating and financing needs; additional debt or equity funding and increased patent-monetization revenue are needed, but financing may not be available on acceptable terms or at all. No numerical earnings or revenue guidance is provided.
- Business risks: Results depend on uncertain patent licensing, settlements and litigation; legal costs may exceed recoveries, and patent claims may be invalidated or narrowed. The PTAB found eight of 15 asserted claims of the ’599 patent and all asserted claims of the ’899 patent invalid in proceedings affecting VTech and Uniden; Spherix filed an appeal in April 2016. The filing also describes counterclaims and later-filed infringement suits.
- Contingencies and financing constraints: Potential contingent payments and recovery-sharing obligations to Rockstar could materially affect liquidity if recoveries occur. The filing says Spherix was then ineligible to sell securities under its Form S-3 shelf until it expected eligibility to resume July 16, 2016; contractual restrictions related to prior financing could further constrain capital raising.
- Internal controls: Management concluded disclosure controls and procedures were ineffective at March 31, 2016, citing inadequate segregation of duties and insufficient controls to ensure material transactions and developments were reflected in the financial statements. Remediation was being developed.
- Strategic and operating commentary: The company described a March 2016 collaboration with Equitable IP Corporation and a review of strategic alternatives, including potential sale, merger, asset divestiture, partnerships or continued operations. Neither a transaction nor successful monetization is assured.
Investor facts to verify
- Confirm the intended issuer: the supplied filing is for Spherix Incorporated, not Dominari Holdings Inc.
- Reconcile the $716,000 common-stockholder loss in the statements with the MD&A’s approximately $0.1 million description, and distinguish both from the $49,000 net loss.
- Assess near-term liquidity, cash burn, financing availability, and the timing and terms of any post-quarter capital raising.
- Check outcomes of the VTech and Uniden appeals and other patent proceedings, including any resulting revenue, legal expense or impairment.
- Verify share count and potential dilution from preferred securities, warrants and options; the filing lists 2.304 million warrants and 289,380 options potentially dilutive.
- Track the effectiveness of control-remediation measures and any subsequent changes in Nasdaq compliance, strategic alternatives or the Equitable arrangement.